Skip to main content

Advertisement

Table 1 Subject characteristics

From: Circadian variations in clinical symptoms and concentrations of inflammatory cytokines, melatonin, and cortisol in polymyalgia rheumatica before and during prednisolone treatment: a controlled, observational, clinical experimental study

  Patients with PMR (n = 10) Control subjects (n = 7)
Sex, female/male 6/4 4/3
Age, years 76 ± 2.2 71 ± 1.6
BMI, kg∙m−2 24.0 ± 1.3 26.7 ± 1.2
Blood pressure (systolic/diastolic, mmHg)
 Before treatment 143 ± 7/88 ± 6 141 ± 10/86 ± 6
 After treatment 147 ± 10/81 ± 3 144 ± 9/85 ± 6
ESR, mm/h   
 Before treatment 72 ± 8a 10 ± 2
 After treatment 21 ± 4b 8 ± 1
CRP, mg/L
 Before treatment 56 ± 7a 3 ± 1
 After treatment 7 ± 2b 1 ± 0.3
PMR-AS
 Before treatment 38 ± 2a 0.2 ± 0.1
 After treatment 5 ± 1b 0 ± 0
  1. Abbreviations: BMI body mass index, CRP C-reactive protein, ESR erythrocyte sedimentation rate, PMR polymyalgia rheumatica, PMR-AS polymyalgia rheumatica activity score [18]
  2. Values are mean ± SEM. Subjects were studied before treatment and during the 14th day of prednisolone treatment (20 mg/day)
  3. a Patients vs control subjects, 2P < 0.05
  4. b After vs before treatment, 2P < 0.05